Abstract
Introduction
Thrombocytopenia (platelet level less than 150000/mm3) is frequently observed in patients with chronic HCV (0.16% to 45%) [1] , often believed to be due to hypersplenism or splenic platelet sequestration however, thrombocytopenia has been observed in HCV without evidence of cirrhosis or splenomegaly. Patients with HCV seem to develop lower platelet levels than patients with other causes of cirrhosis due to bone marrow suppression either by HCV directly, or immune-mediated platelet destruction involving anti-platelet antibodies and/or immune complex associated platelet clearance [2, 3] and impaired thrombopoietin production or activity resulting from hepatocellular damage [4, 5] .
The clinical significance of mild thrombocytopenia (75000-150000/ mm3) is minimal and usually does not interfere with the management and treatment decisions in patients with chronic liver diseases, while moderate and severe thrombocytopenian (<75,000/mm3) could be a limiting factor when considering diagnostic or therapeutic elective procedures in patients with chronic HCV such as liver biopsy, band ligation or surgery due to the increase risk of bleeding. The ability to increase platelet counts could also significantly reduce the need for platelet transfusion [2, 3] .
Danazol is derivative of synthetic steroid ethisterone [6] . It's well tolerated treatment of refractory autoimmune thrombocytopenia associated with many autoimmune diseases [7] .
It has been shown that Danazol may modulate expression of Fc-γ receptors on mononuclear phago-cytes, thereby impending opsonization and destruction of platelets and reduces GP II b -III a complex in patients with autoimmune thrombocytopenia [8, 9] . It may also have an immunomodulatory function which can affect anti-platelet antibody production [10] .
There are some reports regarding hepatotoxic effects of Danazol after more than 2 years of use, but no reports of adverse effects during short time periods [11, 12] .
The aim of this study was to evaluate the efficacy of one month Danazol for increasing and maintaining platelet levels in chronic HCV patients with thrombocytopenia. confidence interval and the level of significance <0.05 as 48 patients who fulfill the inclusion criteria. A P-value less than 0.05 were considered statistically significant.
Results
The A total of 48patients (28 males and 20 females) with chronic HCV and thrombocytopenia <75000/mm3 were included and were given 400 mg Danazol for 1 month. The mean age was 39.30 + 8.7(range 28-60 years) 28 male and 20 female (Table 1) .
One patient developed mild cholestasis after 2 weeks, Danazol was stopped and the patient received ursodeoxycholic acid 15 mg/kg per oral and improved.
From patients did not show any increase in their platelet levels over one month treatment and were considered to be non responders. The mean of platelet levels of all patients had increased significantly from the base time level of 60400 + 13000/mm3 (40000-74000) to a level of 90700 + 14000 /mm3 (65000-14000) at the end of treatment and had decreased to 82400 + 11000 /mm3 (49000-12000) at 3 months after the end of treatment but not statistically significant as shown in table 4 and figure 1. Table 3 shows that the percentage of patients with moderate thrombocytopenia had decreased significantly after Danazol treatment from 83.3% to 20.8%. Table 4 shows also that no statistically significant changes or differences in biochemical parameters after Danazol treatment and after 3 months follow up except significant decrease of serum albumin only after treatment. Table ( 5) shows that the patients younger than 50 years and females had a significantly higher probability of achieving response to
Danazol than older patients and males with odds ratio 19.6 and 1.2 respectively. 
Discussion
Thrombocytopenia is frequently observed in patients with chronic HCV and can limit many diagnostic and therapeutic procedures with increased risk of bleeding. The aim of this clinical trial was to evaluate the efficacy, tolerability and safety of one month Danazol in increasing and maintaining platelet levels in chronic HCV and compensated cirrhosis due to HCV.
The present study included 48 patients with chronic HCV and thrombocytopenia less than 75000/mm3. We consider this platelet level because below this level many procedures could not be done to chronic HCV patients due to the risk of bleeding, which increases with more decrease in platelet level while mild thrombocytopenia ( >75000/ mm3) has a low risk of bleeding.
Alvarez et al. [7] included 49 patients with chronic HCV and thrombocytopenia ≤ 90000/mm3 because patients were included during Pegylated Interferon (Peg IF) treatment and Danazol was given as long as they were still under treatment to prevent stoppage or decrease anti-viral treatment. In the present study, Danazol 400 mg for one month was given on the basis of least effective and safe dose and also for a short time (one month) to minimize risk of severe or undesirable adverse effects and to facilitate any intervention diagnostic or therapeutic procedures by elevation of platelet levels over a short a short time. The ability to increase platelet levels could significantly reduce the need for platelet transfusions and facilitate the use of other medication indicated treatments in patients with liver disease [3] .
Danazol increased platelet levels to 90700 + 31400/mm3 from base time level of 60400 + 11100/mm3 with response rate 79.2% (38 patients). In Alvarez et al. study [7] Danazol result in a higher response rates (85%) and higher platelet levels (121081 + 47320/mm3), this could be explained by longer treatment period (2-11 months), higher basal platelet levels as they included levels ≤ 90000/mm3 and also Danazol 600 mg dose with used for patients with platelet level ≤ 60000/mm3 from the start.
The exact mechanism of Danazol on autoimmune thrombocytopenia is still unknown, but the present results suggest that HCV associated thrombocytopenia has, at least in part, an autoimmune mechanism [2, 3] Thrombopoetin mimics (Romiplostin, Eltrombopag) are TPO -Receptor agonists, which act through increase production of platelets [13] . The use of Eltrombopag in HCV patients with thrombocytopenia is cost-effective [14] . Eltrombopag increased safely platelet levels in dose dependent manner in HCV related compensated liver diseases with thrombocytopenia over 4 weeks of therapy [15, 16] but, although this patient must be well monitored to prevent possible thromboembolic or bone marrow complications or liver failure occurrence [17] . 
Conclusion
Danazol one month treatment is effective for increasing and maintaining platelet levels in chronic HCV and it can be considered a treatment option for thrombocytopenia in HCV compensated liver diseases. 
